Immune Therapeutics, Inc. (IMUN) Fighting the ‘W
Post# of 39
Posted On: 02/26/2016 5:00:12 PM
Immune Therapeutics, Inc. (IMUN) Fighting the ‘War on Cancer’ With Immunotherapy
Immunotherapy is treatment that uses certain parts of a person’s immune system to fight diseases such as cancer. This can be done in a couple of ways, including stimulating your own immune system to work harder or smarter to attack cancer cells or giving your immune system components, such as man-made immune system proteins. Some types of immunotherapy are also sometimes called biologic therapy or biotherapy. Immune Therapeutics, Inc. (OTCQB: IMUN) is a specialty pharmaceutical company involved in the manufacture, distribution and marketing of its novel patented therapies to combat chronic, life-threatening diseases through the activation and modulation of the body’s immune system. The company’s technology platform is built on two different immunotherapies, Low Dose Naltrexone and Methionine-Enkephalin.
Stimulating the body’s immune system remains one of the most promising approaches to addressing the unmet needs of cancers, HIV, inflammatory disease, autoimmune disease and other chronic infectious diseases. “If you take care of your body, then your body will take care of you.” It’s one of the simple clichés we hear all the time from people who are usually healthy. Your immune system is the front, middle and final line of defense against everything your body encounters throughout your lifespan. Nurturing and assisting the immune system with therapies like the ones mentioned above from Immune Therapeutics make much more sense than subjecting your body to harmful artificial treatment methodologies.
According to the Cancer.org website, nearly 14.5 million Americans with a history of cancer were alive on January 1, 2014. About 1,685,210 new cancer cases are expected to be diagnosed in 2016, and about 595,690 Americans are expected to die from cancer in 2016, which translates to about 1,630 people per day. Cancer is the second most common cause of death in the U.S., exceeded only by heart disease, and it accounts for nearly one of every four deaths. The Agency for Healthcare Research and Quality estimates that the direct medical costs (total of all health care expenditures) for cancer in the U.S. in 2013 were $74.8 billion.
These are startling statistics. Most families have experienced the devastating effects of cancer firsthand. There is hope, though. The 5-year relative survival rate for all cancers diagnosed from 2005-2011 was 69 percent, up from 49 percent from 1975-1977. Improvement in survival reflects both the earlier diagnosis of certain cancers and improvements in treatment. Immune Therapeutics’ treatment methodologies are a part of the next generation in the battle against cancer and other chronic, life-threatening diseases.
Learn more by visiting www.immunetherapeutics.com
Please see disclaimer on the QualityStocks website: http://Disclaimer.QualityStocks.com
Immunotherapy is treatment that uses certain parts of a person’s immune system to fight diseases such as cancer. This can be done in a couple of ways, including stimulating your own immune system to work harder or smarter to attack cancer cells or giving your immune system components, such as man-made immune system proteins. Some types of immunotherapy are also sometimes called biologic therapy or biotherapy. Immune Therapeutics, Inc. (OTCQB: IMUN) is a specialty pharmaceutical company involved in the manufacture, distribution and marketing of its novel patented therapies to combat chronic, life-threatening diseases through the activation and modulation of the body’s immune system. The company’s technology platform is built on two different immunotherapies, Low Dose Naltrexone and Methionine-Enkephalin.
Stimulating the body’s immune system remains one of the most promising approaches to addressing the unmet needs of cancers, HIV, inflammatory disease, autoimmune disease and other chronic infectious diseases. “If you take care of your body, then your body will take care of you.” It’s one of the simple clichés we hear all the time from people who are usually healthy. Your immune system is the front, middle and final line of defense against everything your body encounters throughout your lifespan. Nurturing and assisting the immune system with therapies like the ones mentioned above from Immune Therapeutics make much more sense than subjecting your body to harmful artificial treatment methodologies.
According to the Cancer.org website, nearly 14.5 million Americans with a history of cancer were alive on January 1, 2014. About 1,685,210 new cancer cases are expected to be diagnosed in 2016, and about 595,690 Americans are expected to die from cancer in 2016, which translates to about 1,630 people per day. Cancer is the second most common cause of death in the U.S., exceeded only by heart disease, and it accounts for nearly one of every four deaths. The Agency for Healthcare Research and Quality estimates that the direct medical costs (total of all health care expenditures) for cancer in the U.S. in 2013 were $74.8 billion.
These are startling statistics. Most families have experienced the devastating effects of cancer firsthand. There is hope, though. The 5-year relative survival rate for all cancers diagnosed from 2005-2011 was 69 percent, up from 49 percent from 1975-1977. Improvement in survival reflects both the earlier diagnosis of certain cancers and improvements in treatment. Immune Therapeutics’ treatment methodologies are a part of the next generation in the battle against cancer and other chronic, life-threatening diseases.
Learn more by visiting www.immunetherapeutics.com
Please see disclaimer on the QualityStocks website: http://Disclaimer.QualityStocks.com
(0)
(0)Biostax Corp. (BTAX) Stock Research Links
Scroll down for more posts ▼